Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Artisan iris-claw aphakic lens: visual outcomes and complications

Poster Details

First Author: D.Doble Rivera SPAIN

Co Author(s):    C. Molero Langa   D. MIngo Botin   S. Duran Poveda   I. Jiminez-Alfaro Morote   B. Garci­a Sandoval   N. Alejandre Alba     

Abstract Details

Purpose:

To report the visual outcomes, complications and additional treatment needed of Artisan iris-claw aphakic intraocular lens (IOL) implanted at our institution.

Setting:

Hospital Universitario Fundación Jiménez Díaz Madrid, Spain

Methods:

This observational retrospective study comprised patients that underwent iris-claw IOL implantation between 2009 and 2014 with a minimum follow-up of 6 months. Visual and refractive parameters were collected as well as complications and its treatment.

Results:

103 eyes (94 patients) were included, 52.4 % were women. Mean follow-up was 17.7 months (range 6-35). Secondary aphakia was the most common indication (54.4%), followed by anterior chamber IOL exchange (31.1%) and as primary surgery (14.6%). Preoperative best corrected visual acuity was less than 20/60 in 62.1% of eyes, improving over 20/60 in 72.3% of cases one year postoperatively. Mean preoperative spherical equivalent was +8.85±5.7 (SD) diopters (D) and postoperative was -0.46±1.59D. Complications included corneal edema (n=8), elevated intraocular pressure (n=19), macular edema (n=20), retinal detachment (n=1), epiretinal membrane (n=4) and IOL disenclavation (n=1). Mean endothelial cell loss was 20%.

Conclusions:

Iris-claw IOL implantation is a safe and effective procedure for the correction of the aphakic refractive error, with a low rate of vision threatening complications.

Financial Disclosure:

NONE

Back to Poster listing